Prof. Julianne Bayliss

Medical Affairs, GSK, Melbourne, Australia

Email: [email protected]

Qualifications

2008  Ph.D., Monash University, Australia

2005  M.S., Monash University, Australia

2003  B.S., Monash University, Australia

Publications (Selected)

1. Markey, P., Bayliss, J., Jones, D., et al. (2023). Estimating Australian Hospitalization Ratios and Costs for Wildtype SARS-CoV-2 in 2020. Current Problems in Cardiology, 48(11), Article 101917.
2. Wagner, J., Yuen, L., Littlejohn, M., et al. (2021). Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. Hepatology, 73(5), 1652–1670.
3. Wagner, J., Yuen, L., Littlejohn, M., et al. (2020). Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease. Journal of Hepatology, 73(Suppl 1), Meeting Abstract THU327.
4. Bayliss, J., Randhawa, R., Oh, K. B., et al. (2021). Perceptions of vaccine preventable diseases in Australian healthcare: focus on pertussis. Human Vaccines & Immunotherapeutics, 17(2), 344–350.
5. Bayliss, J., Nissen, M., Prakash, D., et al. (2021). Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. Human Vaccines & Immunotherapeutics, 17(1), 176–190.
6. Yuen, L., Revill, P. A., Rosenberg, G., et al. (2020). HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B. Journal of Viral Hepatitis, 27(10), 1061–1070.
7. Bayliss, J., Randhawa, R., Turriani, E., et al. (2019). Australian perceptions of pertussis and vaccine preventable disease in the setting of asthma and COPD. European Respiratory Journal, 54(Suppl 63), Meeting Abstract PA2891.
8. Bayliss, J., Yuen, L., Rosenberg, G., et al. (2017). Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut, 66(11), 2013–2023.
9. Thompson, A. J., Yuen, L., Wong, D., et al. (2016). HBsAg levels vary across the natural history of CHB and are influenced by HBV genotype and the emergence of basal core promoter variants. Hepatology, 64(Suppl 1), Meeting Abstract 608.
10. Yuen, L., Wong, D., Littlejohn, M., et al. (2016). Progression from immune tolerant to HBeAg-negative hepatitis B is associated with increased virus sequence diversity and prevalence of BCP and Precore variants. Hepatology, 64(Suppl 1), Meeting Abstract 575.
11. Audsley, J., Bent, S. J., Littlejohn, M., et al. (2016). Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. AIDS, 30(10), 1597–1606.
12. Bayliss, J., Yuen, L., Rosenberg, G., et al. (2015). Increased Viral Diversity is Associated with Baseline Serology and Reduced Serological Response to Nucleos(t)ide Analogue (NA) Treatment During the Immune Clearance Phase of Chronic Hepatitis B. Hepatology, 62(Suppl 1), Meeting Abstract 1557.
13. Bayliss, J., Rosenberg, G., Yuen, L., et al. (2015). Redefining the Natural History of Chronic Hepatitis B: Using Viral Diversity to Classify Disease and Predict Serological Response to Nucleos(t)ide Analogue (NA) Therapy. Hepatology, 62(Suppl 1), Meeting Abstract 1563.
14. Walsh, R., Hammond, R., Yuen, L., et al. (2015). Mapping HBsAg epitope profiles to predict HBsAg loss/seroconversion in a treatment naive cohort of genotype A chronic hepatitis B (CHB) patients receiving tenofovir disoproxil fumarate (TDF) therapy. Hepatology, 62(Suppl 1), Meeting Abstract 1551.
15. Ayres, A., Yuen, L., Jackson, K. M., et al. (2014). Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. Journal of Viral Hepatitis, 21(11), 809–817.
16. Jegaskanda, S., Ahn, S. H., Skinner, N., et al. (2014). Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e Antigen. Journal of Virology, 88(18), 10412–10420.
17. Bayliss, J., Thompson, A. J., Rosenberg, G., et al. (2014). HBeAg levels predict HBeAg seroconversion during the immune clearance phase of chronic hepatitis B in patients receiving nucleot(s)ide analogue therapy. Hepatology, 60(Suppl 1), Meeting Abstract 1665.
18.  Rosenberg, G., Bayliss, J., Gaggar, A., et al. (2014). Loss of immune tolerance is associated with HBV genotype specific patterns of accumulation of basal core promotor and precore variants, leading to decline in HBeAg and HBsAg levels. Hepatology, 60(Suppl 1), Meeting Abstract 1617.
19. Bayliss, J., Lim, L., Thompson, A. J. V., et al. (2013). Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma. Journal of Hepatology, 59(5), 1022–1028.
20. Yuen, L., Ayres, A., Jackson, K., et al. (2013). Short Duration of Lamivudine for Prevention of HBV Transmission in Pregnancy: Lack of Potency and Selection of Resistance Mutations. Hepatology, 58(Suppl 1), Meeting Abstract 1018.

Profiles Details
https://www.researchgate.net/profile/Julianne-Bayliss


WOS ResearcherID: I-2227-2014